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Purpose of the Study
To assess K statistic of non-invasive imaging evaluations
to diagnose NAFLD by means of US fatty liver indicator
(FLI) score and liver to spleen attenuation ratio by CT.
Methods
Cross-sectional observational study that included all con-
secutive HIV-infected patients seen at a metabolic clinic
who were screened for NAFLD with US and CT in the
same day. HCV, HBV and heavy alcohol users (>20 g/day)
were excluded. With CT, NAFLD diagnosis was defined
with an L/S<1.1. US scanning was performed by a single
operator. Presence and severity of steatosis was evaluated
by a semiquantitative echographic score (FLI) graduated
from 2 to 8. "Sine qua non" condition for the diagnosis of
steatosis was the presence of liver/kidney contrast, gradu-
ated as mild/moderate (score 2) and severe (score 3).
Additional criteria (score 1 each) included posterior atten-
uation of ultrasound beam, vessel blurring, difficult visu-
alization of gallbladder wall or diaphragm and areas of
focal sparing. US NAFLD was diagnosed by the score ≥2.
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Table 1: 
Total NAFLD+ CT NAFLD+ US P-value
Male 34 (73.91) 9 (100) 16 (69.57) .002*
Age, (range) 47.91 (25; 68) 49.55 (37; 57) 48.39 (33; 67) .71§
CCD C, n (%) 9 (19.57) 3 (33.33) 5 (21.74) .45*
Duration of HIV infection 178.26 (52; 278) 172.11 (52; 255) 185.68 (52; 278) .60§
CD4 cell count 554 (153; 1197) 590 (290; 760) 539 (180; 1197) 1†
Log10 VL 2.10 (1.60; 4.72) 2.22 (1.60; 4.50) 2.23 (1.60; 4.72) .98§
NRTI cumulative exp, months (range) 187.97 (8; 614) 182.55 (22; 317) 196.87 (22; 614) .78§
NNRTI cumulative exp, months (range) 47.18 (1; 131) 35 (12; 82) 32.81 (1; 111) .85§
PI cumulative exp, months (range) 68.73 (1; 593) 59.44 (21; 120) 81.82 (1; 593) .59§
AST/ALT 1.00 (0.51; 2.1) .86 (0.51; 1.45) .94 (0.51; 1.54) .55§
Waist 86.54 (69; 113) 90.11 (78; 113) 89.58 (77; 113) .90§
*2-sample test of proportion; § 2-sample unpaired t-test; † Wilcoxon signed-rank test.Page 1 of 2
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46 patients were included. NAFLD prevalence with US
was 19.57% and with CT 50.00%. (Tables 1 and 2).  
K of Cohen coefficent between L/S ≤1.1 and US score ≥2
was 0.21 (agreement = 60.87%), US score ≥3 was 0.45
(agreement = 80.43%), US score ≥4 was 0.29 (agreement
= 80.43%).
Conclusion
Non-invasive imaging agreement between US and CT to
diagnose NAFLD is less than ideal. Best concordance is
found for US ≥3 and L/S ≤1.1. Liver biopsy studies are
needed to validate cut-off of US evaluation and L/S in peo-
ple living with HIV.
Table 2: 
US+ CT+ US- CT- US+ CT- US- CT+ Agreement Kappa C.I. 95%
All Patients n = 70 11 33 22 4 62.86% .23 .03; .43
HCV- n = 46 7 21 16 2 60.87% .22 -.01; .45Page 2 of 2
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